RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to allegations of misleading statements regarding the efficacy of its drug setrusumab in treating Osteogenesis Imperfecta, which led to significant stock price declines following the announcement of study failures [2][4][5][6]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Ultragenyx to contact them to discuss legal options [1]. - The firm is reminding investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Ultragenyx [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Ultragenyx - The complaint alleges that Ultragenyx and its executives violated federal securities laws by making false or misleading statements about the effects of setrusumab and downplaying the risks associated with the Phase III Orbit study [4]. - Ultragenyx's Phase III Orbit study failed to achieve statistical significance for the second interim analysis, leading to a stock price drop of over 25% on July 9, 2025 [5]. - On December 29, 2025, Ultragenyx announced that both its Phase III Orbit and Cosmic Studies did not achieve statistical significance against primary endpoints, resulting in a further stock price decline of over 42% [6][7]. Group 3: Class Action Details - The lead plaintiff in a class action is defined as the investor with the largest financial interest who directs and oversees the litigation on behalf of the class [8]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [8]. Group 4: Call for Information - Faruqi & Faruqi, LLP is also seeking information regarding Ultragenyx's conduct from whistleblowers, former employees, shareholders, and others [9].